Tetsu Watanabe - Taisho Pharmaceutical Executive Director
Director
Mr. Tetsu Watanabe was serving as Executive Director in TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. since June 2015. He is also in charge of Human Resources General Affairs Risk Management Supervisor and Corporationrationrate Communication of the Company. He is also serving as Director and Managing Executive Officer in a subsidiary, TAISHO PHARMACEUTICAL CO., LTD. He previously served as Executive Officer in the Company. since 2015.
| Age | 63 |
| Tenure | 10 years |
| Phone | 81 3 3985 2020 |
| Web | https://www.taisho-holdings.co.jp |
Taisho Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0183 % which means that it generated a profit of $0.0183 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0345 %, meaning that it generated $0.0345 on every $100 dollars invested by stockholders. Taisho Pharmaceutical's management efficiency ratios could be used to measure how well Taisho Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Lawrence Kurzius | Elanco Animal Health | 63 | |
| Prasad Menon | Dr Reddys Laboratories | 74 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Nechemia Peres | Teva Pharma Industries | 61 | |
| Dawn Allen | Haleon plc | 57 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Art Garcia | Elanco Animal Health | 59 | |
| Kalpana Morparia | Dr Reddys Laboratories | 71 | |
| Roberto Mignone | Teva Pharma Industries | 48 | |
| Bharat Doshi | Dr Reddys Laboratories | 71 | |
| BSE CS | HUTCHMED DRC | 72 | |
| Perry Nisen | Teva Pharma Industries | 64 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Bruce Carter | Dr Reddys Laboratories | 77 | |
| Rosemary Crane | Teva Pharma Industries | 60 | |
| Kirk McDonald | Elanco Animal Health | 54 | |
| JeanMichel Halfon | Teva Pharma Industries | 68 | |
| Denise ScotsKnight | Elanco Animal Health | 61 | |
| Shikha Sharma | Dr Reddys Laboratories | 62 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| David Ricks | Elanco Animal Health | 52 | |
Management Performance
| Return On Equity | 0.0345 | |||
| Return On Asset | 0.0183 |
Taisho Pharmaceutical Leadership Team
Elected by the shareholders, the Taisho Pharmaceutical's board of directors comprises two types of representatives: Taisho Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taisho. The board's role is to monitor Taisho Pharmaceutical's management team and ensure that shareholders' interests are well served. Taisho Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taisho Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shigeru Uehara, Vice President and Presidentident of Subsidiary, Director | ||
| Shinichi Tanaka, Gen Communications | ||
| Akira Uehara, President Chairman of Subsidiary, Representative Director | ||
| Jinsei Maruyama, Co Officer | ||
| Tetsu Watanabe, Executive Director | ||
| Jun Kuroda, Ex Director | ||
| Ken Uehara, MD Director | ||
| Hideki Iuchi, G Mang | ||
| Hisashi Umeoka, Director |
Taisho Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Taisho Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0345 | |||
| Return On Asset | 0.0183 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.27 B | |||
| Shares Outstanding | 327.94 M | |||
| Price To Earning | 20.67 X | |||
| Price To Book | 0.57 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 268.2 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Taisho Pink Sheet
If you are still planning to invest in Taisho Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taisho Pharmaceutical's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |